Dasher Neuroscience (思捷優達) Receives US FDA Fast Track Designation for YA-101 in MSA

Dasher Neuroscience-KY announced yesterday (22nd) that its subsidiary’s drug candidate, YA-101, for the treatment of Multiple System Atrophy (MSA), has been granted Fast Track Designation by the US FDA. This status is expected to expedite communication with the FDA and streamline the development process.